Galapagos NV (NASDAQ:GLPG) has earned an average recommendation of “Buy” from the twelve brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $115.17.
A number of equities analysts have commented on GLPG shares. BidaskClub raised shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. BTIG Research reissued a “buy” rating and issued a $118.00 price objective on shares of Galapagos in a research note on Thursday, February 8th. Zacks Investment Research raised shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. ValuEngine cut shares of Galapagos from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $120.00 price objective on shares of Galapagos in a research note on Sunday, October 29th.
Shares of Galapagos (NASDAQ:GLPG) traded down $2.36 during trading hours on Friday, hitting $112.83. 80,200 shares of the company’s stock were exchanged, compared to its average volume of 108,318. Galapagos has a 1-year low of $67.30 and a 1-year high of $121.09. The stock has a market cap of $5,750.00, a PE ratio of -122.64 and a beta of 0.87.
Several institutional investors have recently added to or reduced their stakes in GLPG. Orbimed Advisors LLC lifted its holdings in shares of Galapagos by 84.8% in the 3rd quarter. Orbimed Advisors LLC now owns 523,790 shares of the biotechnology company’s stock worth $53,296,000 after acquiring an additional 240,290 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Galapagos by 130.3% in the 4th quarter. BlackRock Inc. now owns 346,802 shares of the biotechnology company’s stock worth $32,516,000 after acquiring an additional 196,202 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Galapagos by 22.8% in the 4th quarter. Farallon Capital Management LLC now owns 290,000 shares of the biotechnology company’s stock worth $27,190,000 after acquiring an additional 53,784 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Galapagos in the 4th quarter worth about $3,652,000. Finally, Tekla Capital Management LLC lifted its holdings in shares of Galapagos by 180.0% in the 4th quarter. Tekla Capital Management LLC now owns 53,200 shares of the biotechnology company’s stock worth $4,988,000 after acquiring an additional 34,200 shares during the last quarter. Hedge funds and other institutional investors own 19.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Galapagos NV (GLPG) Given Consensus Rating of “Buy” by Analysts” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/21/galapagos-nv-glpg-given-consensus-rating-of-buy-by-analysts.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.